What is CKD staging and what do the stages mean?

CKD (Chronic Kidney Disease) is staged G1 through G5 based on eGFR (estimated Glomerular Filtration Rate). Stage G1 is normal kidney function (eGFR ≥90) with markers of kidney damage. G2 is mildly reduced function (eGFR 60–89). G3a is mildly-to-moderately reduced (eGFR 45–59). G3b is moderately-to-severely reduced (eGFR 30–44). G4 is severely reduced (eGFR 15–29). G5 is kidney failure (eGFR <15 or dialysis). Albuminuria category (A1–A3) is also used to assign overall risk. According to KDIGO 2024 guidelines, all eGFR values should be confirmed over at least 3 months before a CKD diagnosis is made.

How do I calculate eGFR for CKD staging?

eGFR (estimated Glomerular Filtration Rate) is calculated using the CKD-EPI 2021 equation, which uses serum creatinine, age, and sex — but no longer includes race as a variable, following KDIGO 2024 and NKF-ASN 2021 recommendations. The formula is: eGFR = 142 × min(Scr/κ, 1)^α × max(Scr/κ, 1)^(−1.200) × 0.9938^Age × (1.012 if female), where κ is 0.7 for females and 0.9 for males. CKDPartner calculates this automatically from lab values. Normal eGFR is ≥60 mL/min/1.73m²; values below this threshold for 3+ months indicate CKD.

What foods should CKD patients avoid?

CKD patients typically need to limit potassium, phosphorus, sodium, and protein depending on their stage. High-potassium foods to limit (especially at G3b–G5): bananas, oranges, potatoes, tomatoes, dairy. High-phosphorus foods to limit: processed meats, dark colas (contain inorganic phosphate), fast food, dairy. A key insight from research (Moe et al., JASN 2011): plant-based phosphorus (phytate-bound) is only 30% absorbed, while inorganic phosphate food additives (in processed food) are up to 100% absorbed and most dangerous. Double-boiling vegetables can reduce potassium by 30–50%. CKDPartner models the precise bioavailability of each food category for personalized recommendations.

Is Metformin safe for CKD patients?

Metformin safety in CKD depends on eGFR level. According to the 2016 FDA label update and KDIGO 2024 guidelines: Metformin is safe at eGFR ≥45 with normal dosing. At eGFR 30–44, Metformin can be continued but dose should not exceed 1000mg/day. At eGFR <30, Metformin is contraindicated due to lactic acidosis risk. CKDPartner automatically flags Metformin risks based on the user's entered eGFR value. Notably, dose reduction should also occur with acute illness, dehydration, or use of iodinated contrast agents even if baseline eGFR is acceptable.

Are SGLT2 inhibitors (like dapagliflozin) recommended for CKD?

Yes. SGLT2 inhibitors are now a cornerstone of CKD management regardless of diabetes status. The DAPA-CKD trial (Heerspink et al., NEJM 2020) demonstrated that dapagliflozin reduced the composite risk of sustained eGFR decline of ≥50%, end-stage kidney disease, or death from renal or cardiovascular causes by 39% compared to placebo. The EMPA-KIDNEY trial confirmed similar benefits for empagliflozin. KDIGO 2024 recommends SGLT2 inhibitors as first-line therapy for CKD patients with eGFR ≥20, T2DM and proteinuria, or heart failure. CKDPartner displays SGLT2 inhibitor eligibility based on the patient's current eGFR.

What is UACR and why is it important in CKD?

UACR (Urine Albumin-to-Creatinine Ratio) measures protein leakage into the urine and is a critical marker of CKD severity. KDIGO defines three albuminuria categories: A1 (normal to mildly increased) — UACR 300 mg/g (macroalbuminuria). Combined with eGFR stage (G1–G5), the UACR category assigns overall CKD risk from low to very high. UACR >300 mg/g is associated with 10x higher cardiovascular mortality compared to normal UACR. CKDPartner displays the full G+A risk heat map according to KDIGO 2024 guidelines.

How can I slow down CKD progression?

Multiple evidence-based interventions significantly slow CKD progression: (1) Blood pressure control — target <120/80 mmHg (SPRINT Trial); systolic BP reduction from 140 to 120 reduces CKD progression by 30%. (2) SGLT2 inhibitors — reduce progression by 39% (DAPA-CKD, NEJM 2020). (3) Low-protein diet — 0.6–0.8g/kg/day reduces progression by approximately 25% at G3b–G4 (MDRD Study). (4) RAASi therapy (ACE inhibitors or ARBs) — reduce proteinuria and slow progression. (5) Phosphorus restriction — high phosphate intake accelerates vascular calcification and CKD progression. (6) Avoiding nephrotoxins — NSAIDs, contrast agents, aminoglycosides, proton pump inhibitors at high doses.

What is cardiorenal syndrome and CKM staging?

Cardiorenal syndrome (CRS) describes the bidirectional relationship between heart failure and kidney disease — each organ worsening the other. The AHA/ACC 2023 introduced Cardiovascular-Kidney-Metabolic (CKM) syndrome staging (Stage 0–4) integrating CKD, metabolic syndrome, and cardiovascular risk into a unified framework. Stage 0: No risk factors. Stage 1: Overweight/obesity or prediabetes. Stage 2: CKD G1–G4 or metabolic syndrome. Stage 3: High cardiovascular risk without clinical CVD. Stage 4: Established cardiovascular disease. CKDPartner incorporates CKM staging to identify patients who benefit most from cardioprotective medications like SGLT2 inhibitors and finerenone.

Is CKDPartner free to use?

Yes. CKDPartner is completely free to use with no login or credit card required. All calculators (eGFR, UACR, dietary mineral tracking, medication safety checking) are unlimited. AI-powered clinical deliberation using GPT-4o, Claude, and Gemini is free for 15 queries on the shared free tier. For unlimited AI deliberation, users can enter their own API key from OpenAI, Anthropic (Claude), or Google (Gemini) — a feature called BYOK (Bring Your Own Key). No patient data is stored on CKDPartner servers; all processing happens in the user's browser.

What is the difference between eGFR and creatinine in kidney disease?

Serum creatinine and eGFR both measure kidney filtration capacity but serve different purposes. Serum creatinine (normal range: 0.6–1.2 mg/dL for adults) is a raw waste product filtered by kidneys; it rises as kidney function declines, but the relationship is nonlinear and depends heavily on muscle mass. eGFR (estimated Glomerular Filtration Rate) is a calculated value that normalizes creatinine for age, sex, and body size — providing a standardized measure of kidney function in mL/min/1.73m². Critically, eGFR can remain normal even when creatinine is elevated, and vice versa. KDIGO recommends using eGFR (not creatinine alone) for CKD staging and monitoring. CKDPartner calculates eGFR from serum creatinine using the 2021 CKD-EPI equation.

What is the 'Triple Whammy' drug interaction in CKD?

The 'Triple Whammy' is the concurrent administration of an NSAID (which vasoconstricts the afferent arteriole), an ACE inhibitor or ARB (which vasodilates the efferent arteriole), and a diuretic (which causes volume depletion). This combination severely reduces glomerular perfusion pressure and is a major trigger for acute kidney injury (AKI) in CKD patients.

Why is Finerenone (Kerendia) prescribed in CKD?

Finerenone is a non-steroidal mineralocorticoid receptor antagonist (MRA) indicated to reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, non-fatal myocardial infarction, and hospitalization for heart failure in adults with chronic kidney disease associated with type 2 diabetes. Per KDIGO 2024, it should not be initiated if baseline serum potassium is >5.0 mEq/L, and should be held if potassium rises above 5.5 mEq/L.

What serum potassium levels are dangerous in CKD?

Normal serum potassium is 3.5 to 5.0 mEq/L. Levels between 5.1 and 5.5 mEq/L represent mild hyperkalemia, requiring a low-potassium diet. Levels between 5.6 and 5.9 mEq/L represent moderate hyperkalemia, requiring immediate clinical review and possible potassium binders or medication adjustments (like holding RAASi or Finerenone). Serum potassium >=6.0 mEq/L is severe hyperkalemia, representing a medical emergency that requires an urgent ECG.

What are the symptoms of hyperkalemia?

Hyperkalemia is often called a 'silent killer' because it is frequently asymptomatic until it becomes severe. When symptoms do occur, they include muscle weakness, fatigue, numbness or tingling (paresthesia), nausea, difficulty breathing, chest pain, and heart palpitations. Severe hyperkalemia can cause life-threatening cardiac arrhythmias or cardiac arrest.

What are the symptoms of metabolic acidosis in CKD?

Mild metabolic acidosis may have no symptoms. As it worsens, symptoms can include chronic fatigue, muscle weakness, loss of appetite, nausea, vomiting, rapid breathing (Kussmaul respiration), and mental confusion. Long-term metabolic acidosis contributes to bone loss (osteopenia), muscle wasting, and accelerated decline in kidney function.

How is metabolic acidosis treated in kidney patients?

Per KDIGO 2024 guidelines, metabolic acidosis is treated when serum bicarbonate falls below 22 mEq/L, targeting a range of 23 to 29 mEq/L. Treatment includes oral alkali therapy (such as sodium bicarbonate or sodium citrate tablets) and dietary modifications to reduce the Potential Renal Acid Load (PRAL) by increasing consumption of alkali-producing fruits and vegetables.

What is the Potential Renal Acid Load (PRAL)?

PRAL is a formula that calculates the net amount of acid or alkali produced by a food after metabolism. Foods with a positive PRAL (meats, fish, eggs, cheese, grains) produce acid in the body. Foods with a negative PRAL (most fruits, vegetables, herbs) produce alkali, acting as natural buffers. Minimizing positive PRAL foods helps manage metabolic acidosis in CKD.

What is the difference between haemodialysis and peritoneal dialysis?

Haemodialysis uses an external machine with a filter (dialyzer) to clean the blood, usually done in a clinic 3 times a week for 4 hours, or at home. Peritoneal dialysis uses the lining of the patient's abdomen (peritoneum) as a filter; a sterile fluid is introduced through a catheter, left to absorb waste, and then drained, usually performed daily at home.

When is dialysis usually started in CKD?

Dialysis initiation should be symptom-driven rather than based on a strict eGFR threshold, as demonstrated by the IDEAL trial. Symptoms indicating the need for dialysis include uremic pericarditis, severe metabolic acidosis, refractory fluid overload, progressive malnutrition, or intractable nausea/vomiting. It is typically considered when eGFR falls below 15 mL/min/1.73m² (Stage G5).

What is Conservative Kidney Management (CKM)?

Conservative Kidney Management (CKM) is a holistic care pathway for advanced CKD (Stage G5) that focuses on symptom control, quality of life, and advanced care planning without initiating dialysis or kidney transplantation. It is an active, evidence-based treatment option chosen by patients who have severe comorbidities or for whom dialysis offers minimal survival benefit.

What is an AV fistula and why is it preferred for dialysis?

An arteriovenous (AV) fistula is a surgical connection made between an artery and a vein, usually in the arm, to create a durable access point for haemodialysis. It is preferred over catheters and grafts because it has lower rates of infection, lower risk of blood clots, provides better blood flow, and lasts significantly longer.

How does dialysis affect protein requirements?

Pre-dialysis CKD patients (Stages G3-G5) are placed on a low-protein diet (0.6-0.8 g/kg/day) to minimize uremic waste. However, once dialysis begins, protein requirements increase to 1.1-1.4 g/kg/day. This is because dialysis removes amino acids and proteins from the blood, and high protein intake is required to prevent protein-energy wasting (PEW).

What does phosphorus bioavailability mean?

Bioavailability refers to the proportion of dietary phosphorus that is actually absorbed by the human digestive tract. Phytate-bound plant phosphorus has low bioavailability (30-40% absorbed), organic animal protein phosphorus has moderate bioavailability (60-80% absorbed), and inorganic chemical phosphate additives have 100% bioavailability.

What are the dangers of inorganic phosphate additives?

Inorganic phosphate additives (like STPP, sodium phosphate, and phosphoric acid) are widely used in processed meats, fast food, packaged baked goods, and colas. Because they are not bound to protein, they are 100% absorbed in the intestines, causing rapid rises in serum phosphorus that damage blood vessels and accelerate cardiovascular disease.

How do phosphate binders work?

Phosphate binders are medications taken with meals. They bind to dietary phosphorus in the gastrointestinal tract, forming insoluble complexes that are excreted in the stool rather than absorbed into the bloodstream. Common binders include calcium carbonate, sevelamer carbonate, and lanthanum carbonate.

What does UACR stage A1, A2, and A3 mean?

UACR categories define the level of albumin protein in urine: A1 ( 300 mg/g) is severely increased, representing significant glomerular damage and high risk for CKD progression and cardiovascular disease.

What are the symptoms of early-stage CKD?

Early-stage CKD (Stages G1, G2, and G3a) is typically asymptomatic. Most patients have no symptoms at all, and the disease is only detected through routine blood tests (measuring creatinine/eGFR) or urine tests (measuring protein/UACR).

What are the symptoms of advanced kidney failure?

Symptoms of advanced kidney failure (Stages G4 and G5) include fatigue, swollen ankles or hands (edema), shortness of breath, changes in urination frequency, metallic taste in the mouth, loss of appetite, nausea, vomiting, muscle cramps, itchy skin, and difficulty concentrating.

How does high blood pressure damage kidneys?

High blood pressure (hypertension) damages the delicate blood vessels in the kidneys (glomeruli), reducing their ability to filter waste. This triggers a cycle where kidney damage increases blood pressure further, accelerating kidney function decline. KDIGO 2024 recommends a target systolic blood pressure of <120 mmHg for most CKD patients.

How does diabetes cause kidney disease (diabetic nephropathy)?

High blood glucose levels damage the kidneys' filtration units (nephrons) over time by causing hyperfiltration, inflammation, and scarring (glomerulosclerosis). This leads to protein leaking into the urine (albuminuria) and a gradual decline in eGFR. Diabetes is the leading cause of chronic kidney disease worldwide.

CKDPartner — Free CKD Staging, eGFR Calculator & Renal Diet Tool

CKDPartner is a free clinical decision support tool for chronic kidney disease (CKD) patients, caregivers, and nephrologists. Built on KDIGO 2024 guidelines, it provides eGFR staging, renal dietary planning, cardiorenal medication safety checks, and AI-powered clinical deliberation.

Key Features

eGFR Calculator (CKD-EPI 2021, race-neutral)
CKD staging G1–G5 with UACR albuminuria A1–A3 risk matrix
Potassium and phosphorus dietary tracking (bioavailability-adjusted)
Medication safety alerts (Metformin, SGLT2i, RAASi, NSAIDs)
Multi-LLM AI deliberation (GPT-4o, Claude, Gemini)
Printable physician consultation report

Enable JavaScript to use the full interactive application.